THE Esses Pharmacy (pvt) Ltd

THE Esses Pharmacy (Pvt) Ltd is a pharmaceutical importer and distributor based in Colombo, Sri Lanka. Specializing in the importation of finished pharmaceutical formulations, the company plays a pivotal role in supplying critical medications to the Sri Lankan market. Their primary focus is on oncology treatments, ensuring the availability of essential cancer therapies within the country.

The company's headquarters are located at No. 343 Galle Road, Bambalapitiya, Colombo 04, Sri Lanka. This strategic location positions them centrally within Colombo, facilitating efficient distribution and accessibility. While specific information regarding a parent company is not readily available, THE Esses Pharmacy (Pvt) Ltd operates as an independent entity, dedicated to meeting the pharmaceutical needs of the Sri Lankan population.

THE Esses Pharmacy (Pvt) Ltd maintains a centralized distribution model from their Colombo headquarters. This approach enables them to effectively manage inventory and coordinate logistics for nationwide distribution. While detailed information about additional warehouse locations or logistics capabilities is not specified, their strategic position in Colombo suggests a focus on optimizing supply chain operations to meet the demands of the Sri Lankan market.

In Sri Lanka's pharmaceutical supply chain, THE Esses Pharmacy (Pvt) Ltd functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, they ensure the availability of essential medications, particularly in the oncology sector. Their role is crucial in bridging the gap between global pharmaceutical manufacturers and the local healthcare system, facilitating access to life-saving treatments for patients across Sri Lanka.

THE Esses Pharmacy (Pvt) Ltd exhibits a high degree of supplier concentration, sourcing all their imported pharmaceutical formulations from a single supplier, PLEASANT EXPORTS. This exclusive sourcing strategy, with a total import value of $924K USD across 30 shipments, indicates a strong and stable relationship between the two entities. However, such dependency on a single supplier may pose risks, including potential supply chain disruptions or pricing fluctuations. The consistent volume of imports suggests a mutually beneficial partnership, yet it also underscores the importance of evaluating and mitigating risks associated with supplier concentration.

The resilience of THE Esses Pharmacy (Pvt) Ltd's supply chain is closely tied to their exclusive relationship with PLEASANT EXPORTS. While this partnership ensures a steady supply of pharmaceutical formulations, the lack of alternative suppliers may expose the company to risks such as supply interruptions or regulatory changes affecting their sole supplier. The diversity of formulations imported, with 149 unique products, indicates a broad portfolio, which can help mitigate some risks. However, the absence of backup suppliers and potential exposure to shipping route disruptions highlight areas where the company's supply chain resilience could be enhanced.

THE Esses Pharmacy (Pvt) Ltd's sourcing pattern, characterized by exclusive reliance on PLEASANT EXPORTS, positions them as a significant buyer of specific pharmaceutical formulations, notably in the oncology category. This concentrated sourcing strategy may offer advantages such as favorable pricing and tailored product offerings. For Indian exporters, this presents an opportunity to diversify their client base by offering alternative products or formulations not currently supplied by PLEASANT EXPORTS, thereby reducing the risk associated with single-source dependency. Additionally, establishing relationships with THE Esses Pharmacy (Pvt) Ltd could lead to increased market penetration in Sri Lanka, especially in therapeutic areas where the company seeks to expand its portfolio.

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing the pharmaceutical sector in Sri Lanka. Established in 2015 through an Act of Parliament, the NMRA is responsible for ensuring the safety, efficacy, and quality of medicines, medical devices, and related products within the country. The NMRA regulates the manufacturing, importation, distribution, and sale of medicines, playing a crucial role in protecting public health by enforcing standards and guidelines for pharmaceutical products. (nmra.gov.lk)

Import licensing in Sri Lanka is managed by the NMRA, which requires all pharmaceutical products to be registered before they can be imported and marketed. This process ensures that imported medicines meet the necessary safety, efficacy, and quality standards. The NMRA recognizes Good Manufacturing Practice (GMP) certifications from reputable authorities, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply THE Esses Pharmacy (Pvt) Ltd must ensure that their manufacturing facilities hold valid GMP certifications recognized by the NMRA to comply with import regulations. (nmra.gov.lk)

The NMRA mandates that all pharmaceutical products imported into Sri Lanka undergo batch testing to verify their quality and compliance with established standards. Stability studies are also required to ensure that medicines maintain their efficacy and safety throughout their shelf life. Labeling requirements include providing information in English and Sinhala, ensuring accessibility and understanding for the local population. Additionally, serialization mandates are enforced to enhance traceability and prevent counterfeit products from entering the market. (nmra.gov.lk)

Between 2024 and 2026, the NMRA has implemented several policy changes affecting pharmaceutical imports into Sri Lanka. These include stricter enforcement of GMP certification requirements, updates to import licensing procedures to streamline the registration process, and enhanced monitoring of product labeling to ensure compliance with international standards. These regulatory changes aim to improve the quality and safety of medicines available in Sri Lanka, impacting both local and international pharmaceutical suppliers. (nmra.gov.lk)

THE Esses Pharmacy (Pvt) Ltd's focus on oncology products, particularly carboplatin, thalidomide, and lomustine, aligns with the significant demand for cancer treatments in Sri Lanka. The high import value of carboplatin ($900K) and the substantial market share of lomustine (9.9%) indicate a strategic emphasis on these critical therapies. This product strategy is driven by the pressing need for effective cancer treatments in the region, positioning THE Esses Pharmacy (Pvt) Ltd as a key supplier in this therapeutic area.

THE Esses Pharmacy (Pvt) Ltd's sourcing strategy is heavily reliant on a single supplier, PLEASANT EXPORTS, for their pharmaceutical formulations. This approach suggests a preference for consistent product quality and supply reliability. The exclusive sourcing from India indicates a strategic choice to leverage the country's established pharmaceutical manufacturing capabilities and cost advantages. However, this concentration also exposes the company to potential risks associated with single-source dependency.

By focusing on high-value oncology products, THE Esses Pharmacy (Pvt) Ltd serves a niche segment of the Sri Lankan pharmaceutical market. Their role as a primary importer and distributor of critical cancer therapies positions them as a vital partner for hospitals, oncology clinics, and healthcare providers requiring specialized medications. This market positioning underscores their commitment to addressing the specific needs of cancer patients in Sri Lanka.

For new Indian suppliers, there is a realistic opportunity to engage with THE Esses Pharmacy (Pvt) Ltd by offering alternative products or formulations not currently supplied by PLEASANT EXPORTS. Identifying gaps in THE Esses Pharmacy (Pvt) Ltd's current sourcing, such as additional oncology treatments or other therapeutic areas, could present avenues for collaboration. Establishing a relationship would require demonstrating product quality, compliance with NMRA regulations, and the ability to meet the company's supply chain requirements.

Indian exporters aiming to supply THE Esses Pharmacy (Pvt) Ltd must ensure that their manufacturing facilities hold valid GMP certifications recognized by the NMRA, such as WHO GMP or PIC/S certifications. Products must be registered with the NMRA, adhering to the necessary safety, efficacy, and quality standards. Additionally, compliance with labeling requirements, including information in English and Sinhala, and adherence to serialization mandates are essential for market entry. (nmra.gov.lk)

To establish a relationship with THE Esses Pharmacy (Pvt) Ltd, Indian exporters should initiate contact by providing detailed product information, including GMP certifications and NMRA registration status. Participating in tenders and responding to requests for proposals can demonstrate commitment and capability. Developing a comprehensive regulatory filing strategy that aligns with NMRA requirements is crucial. Setting realistic timelines for product registration and market entry, considering the NMRA's processing times and regulatory procedures, will facilitate a smoother collaboration.